Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials

about

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials

Item

http://www.wikidata.org/entity/Q58803268

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Dose modification and dose int ...... multinational phase III trials

@en

Dose modification and dose int ...... multinational phase III trials

@nl

type

Item

label

Dose modification and dose int ...... multinational phase III trials

@en

Dose modification and dose int ...... multinational phase III trials

@nl

prefLabel

Dose modification and dose int ...... multinational phase III trials

@en

Dose modification and dose int ...... multinational phase III trials

@nl

P1476

Dose modification and dose int ...... multinational phase III trials

@en

P2093

Carlo Albera

http://www.w3.org/2001/XMLSchema#string

Frank Gilberg

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Swigris

http://www.w3.org/2001/XMLSchema#string

Klaus-Uwe Kirchgaessler

http://www.w3.org/2001/XMLSchema#string

Lisa H Lancaster

http://www.w3.org/2001/XMLSchema#string

Marilyn K Glassberg

http://www.w3.org/2001/XMLSchema#string

Paul W Noble

http://www.w3.org/2001/XMLSchema#string

Steven D Nathan

http://www.w3.org/2001/XMLSchema#string

Susan L Limb

http://www.w3.org/2001/XMLSchema#string

Ute Petzinger

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.

P304

e000323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJRESP-2018-000323

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30116539

http://www.w3.org/2001/XMLSchema#string

P932

6089326

http://www.w3.org/2001/XMLSchema#string